Stock 2105 LAEKNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Laekna, Inc.

Equities

2105

KYG5340S1093

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:39 2024-05-28 EDT 		5-day change 1st Jan Change
7.04 HKD +0.14% Intraday chart for Laekna, Inc. -9.16% -64.62%
05-23 US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8% MT
05-23 Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Laekna, Inc.

US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8% MT
Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer CI
Laekna Gets Investigational New Drug Approval from Chinese Regulator for Obesity Drug MT
Lekna, Inc. Obtains IND Approval from the CDE for LAE102 CI
Laekna Scores FDA Nod for Obesity Drug LAE102 MT
Lekna, Inc. Obtains Investigational New Drug Approval from the U.S. Food and Drug Administration for LAE102 CI
Laekna Shrinks Loss in Fiscal 2023 MT
Laekna, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Laekna Submits New Drug Application to US FDA for Anti-Obesity Drug MT
Lekna, Inc. Submits Investigational New Drug Application for LAE102 for the Treatment of Obtains Treatment of Obtains Treatment to the U.S. Food and Drug Administration CI
Laekna's LAE102 IND Application Accepted by Chinese Drug Authorities MT
Laekna, Inc. Announces the Centre for Drug Evaluation of the National Medical Products Administration of China Accepts the Investigational New Drug Application for Lae102 CI
Laekna, Inc. Announces Management Changes CI
Laekna's Phase 2 Trial for Ovarian Cancer Treatment Shows Reduced Risk of Disease Progression; Shares Plunge 34% MT
Laekna, Inc. Announces Top-Line Data of the Global MRCT Phase II Registrational Trial (PROFECTA-II) in Both the U.S. and China CI
Laekna, Inc. Announces Appointment of Chau Kwok Keung as Chief Financial Officer CI
Laekna, Inc. Announces Executive Changes CI
326,372,350 Shares of Laekna, Inc. are subject to a Lock-Up Agreement Ending on 29-DEC-2023. CI
Laekna, Inc.(SEHK:2105) added to S&P Global BMI Index CI
Laekna Presents Data from Phase 1B Trial for Cancer Treatment MT
Laekna, Inc. Announces Presentation of the Study Results from Core Product Furesertib at the 2023 SABCS CI
Laekna, Inc. Announces Resignation of Ji Dongmei as Non-Executive Director CI
Laekna Shrinks Loss in H1 MT
Laekna, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hong Kong Stocks Drop Over Weak China Data Bets; Laekna Closes 20% Higher at Debut MT

Chart Laekna, Inc.

Chart Laekna, Inc.
More charts

Company Profile

Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer and liver disease. The Company is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The Company's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer. The Company mainly conducts its businesses in China, the United States, Europe and South Korea.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LAEKNA, INC. Stock Laekna, Inc.
-64.62% 351M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.83% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.80% 106B
BIONTECH SE Stock BioNTech SE
-10.84% 23.4B
ARGENX SE Stock argenx SE
-1.69% 22.1B
GENMAB A/S Stock Genmab A/S
-10.23% 18.34B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.92% 16.59B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.11% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.62% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+17.53% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2105 Stock
  4. News Laekna, Inc.
  5. Laekna Submits New Drug Application to US FDA for Anti-Obesity Drug